Ozempic, Wegovy, and compounded semaglutide target the glucagon-like peptide-1 receptornot thyroid-stimulating hormone or thyroid peroxidase
Release and Function of GLP-1 GLP-1 is a hormone, or chemical messenger, that gets released during digestion
This phenomenon isnt unique to one state
In January 2025, the FDA approved an injectable form of semaglutide (Ozempic) specifically for managing chronic kidney disease in type 2 diabetes patients
Adequate hydration helps prevent kidney problems, reduces constipation, and supports overall digestive health during treatment
Compounded drug products are not approved or evaluated for safety, effectiveness, or quality by the FDA Compounded Semaglutide (GLP-1) Injections A once-weekly GLP-1 injection designed to help reduce appetite, improve metabolic health, and support sustainable weight loss under licensed medical supervision